"The ambition is to try to have such vaccines available in a year from now. This might be possible at least for the frontrunners (of vaccine developers)," Cavaleri said.
"These are just forecasts based on what we are seeing and what we expect might happen. But again I have to stress that this is a best-case scenario, (and) we know not all vaccines that enter into development may make it till the end and will come to the authorization," he added.
In France, a vaccine-related controversy made headlines after Sanofi CEO Paul Hudson told U.S. media on Wednesday that "the U.S. government has the right to the largest pre-order because it's invested in taking the risk."
"The declaration of Sanofi boss has upset the President of the Republic (Emmanuel Macron) because this vaccine must be a global public good...The vaccine should be available to everyone at the same time," an official at the Elysee told French media.
"A vaccine against COVID-19 should be a public good for the world. The equal access of all to the virus (vaccine) is non-negotiable," French Prime Minister Edouard Philippe wrote on Tweeter.
Philippe added that Sanofi's chairman Serge Weinberg had given him "all the necessary assurances" with regard to the distribution in France of any potential Sanofi vaccine.
Sanofi is among dozens of drug companies that are currently working on vaccine projects against COVID-19. One of its projects involves a partnership with Biomedical Advanced Research and Development Authority (BARDA), a U.S. Department of Health and Human Services office for preparedness and response.
【国际英语资讯:Spotlight: European Region infections top 1.8 mln amidst vaccine hope, controversy】相关文章:
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15